OncoMatch/Clinical Trials/NCT07218926
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
Is NCT07218926 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies multiple treatments including IDRX-42 and Sunitinib for gastrointestinal neoplasms.
Treatment: IDRX-42 · Sunitinib — The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) when compared to another drug named sunitinib. The study will see if IDRX-42 works well and is safe for participants whose GIST has spread or cannot be surgically removed, and who have already taken the drug imatinib. Participants whose disease worsens after receiving sunitinib in this study may cross over to receive GSK6042981, at investigator's discretion and if additional eligibility criteria are met.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Gastrointestinal Stromal Tumor
Biomarker criteria
Excluded: KIT wild-type
GIST that is both KIT and PDGFRA wild-type
Excluded: PDGFRA wild-type
GIST that is both KIT and PDGFRA wild-type
Excluded: PDGFRA exon 18 activating mutation
known to harbor an activating PDGFRA exon 18 mutation
Prior therapy
Must have received: imatinib (imatinib) — first-line treatment of unresectable/metastatic disease
Documented disease progression on or intolerance to imatinib administered for first-line treatment of unresectable/metastatic disease
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- GSK Investigational Site · Phoenix, Arizona
- GSK Investigational Site · La Jolla, California
- GSK Investigational Site · Los Angeles, California
- GSK Investigational Site · San Francisco, California
- GSK Investigational Site · New Haven, Connecticut
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07218926 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received imatinib.
Are patients with KIT alterations eligible?
No. KIT wild-type is an exclusion criterion.
Are patients with PDGFRA alterations eligible?
No. PDGFRA wild-type is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages